Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
about
A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chipsSignaling by target of rapamycin proteins in cell growth controlRapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cellsThe C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylationRapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cellsA novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulinMammalian target of rapamycin: a central node of complex signaling cascadesProtean PTEN: form and functionSkp2: a novel potential therapeutic target for prostate cancerThe mTOR signalling pathway in human cancerNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyMolecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.mTOR signaling in growth control and diseaseThe TSC1-TSC2 complex: a molecular switchboard controlling cell growthAberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomasTargeting the mTOR signaling network for cancer therapyCCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signalingRapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signalingBalancing Akt with S6K: implications for both metabolic diseases and tumorigenesisTyrosine kinase - Role and significance in Cancer.New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonistsThe fate of chemoresistance in triple negative breast cancer (TNBC)The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesWill kinase inhibitors make it as glioblastoma drugs?CIViC databaseThe discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug designPhosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicPredicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activationTOR controls transcriptional and translational programs via Sap-Sit4 protein phosphatase signaling effectorsA genome-wide screen for regulators of TORC1 in response to amino acid starvation reveals a conserved Npr2/3 complexJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesDrugging the addict: non-oncogene addiction as a target for cancer therapyTarget of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1The concept of synthetic lethality in the context of anticancer therapymTOR and cancer therapy
P2860
Q24294219-4C69BFCD-3083-437D-B2C0-E0D2F8CB3F6EQ24314346-2837D144-7049-4DAC-9CD6-4E071DEAD4CDQ24522447-0B508F11-FA44-4007-AA17-1B0A55828C52Q24538036-FD5044E2-B182-4FE0-B302-4041B2D35B4BQ24540159-ACB57756-8DC2-4FBD-B554-2DD21FD5BE93Q24550891-0364262F-BE44-48F9-BD1B-E608F85C23D4Q24554323-C8C20155-69CD-4457-912A-6273D619CA8EQ24554359-1D02DD34-B7D3-4C81-A598-A13FF56540FFQ24599904-E92637CC-884B-4C10-9108-1487E2C39F56Q24601702-7998B82C-9CC3-4C31-9E3E-0E1D8E525C10Q24613810-365523D3-60E4-4B29-8802-AF3D6768D5DAQ24625558-AE5EC82F-21D6-4E41-977D-42A6D7A80DBCQ24627306-4665EE60-5F91-49D7-8D00-F7C36DF00B37Q24628724-B51C43CF-BE47-43F0-9608-6120C11D488CQ24633947-27AEC04D-C915-429A-8158-B280F17BE78CQ24634174-763C0012-E5F8-4180-B079-F5B65A788BE7Q24645204-B169CA0B-A7B3-4493-9890-1069136CD9D1Q24658269-F44EC6C2-D80B-43B5-A5FB-8D87072F60D6Q24658334-D3A4050B-0767-45E6-993E-CBAE71C062BFQ24672058-14FB6FE3-EDF8-406A-B22E-8E4D3599C2D4Q24673299-D69D6996-2B43-4A61-AE9C-5780C5FF91C2Q24676203-F4DAE8D5-9C1D-4836-B6AC-DF79FC5AC9E0Q24791430-42E78EA9-7F2D-473C-8E81-1AD5AB40118EQ24806542-57175621-8176-4BFA-85E3-E96CB9BCC16FQ26775232-E11D9287-E026-4D70-B2C2-7FD4BB082445Q26851852-8CEA6491-F147-4F97-B96D-7A87C91C73F1Q26852437-65B3BEAD-656B-460A-9EF8-DEF0096FE6CCQ27012684-F8E14CF4-03DF-4901-918E-85ED8C32D2A9Q27612411-2F2585FE-9D36-4370-91B1-97A33D022B5FQ27680079-99C950AB-77EF-4CF6-BE23-F734B61C2D59Q27824826-1D0CF7D8-C5B9-470C-82CC-4F9A102F64F2Q27851999-267AF1F6-8ECB-4507-811A-2D10E17277F4Q27852528-294527EE-8313-4E84-913B-32D8F2EC5638Q27933053-7E01B9D6-C934-4573-B38C-0D2E43F25152Q27938995-44582D07-BC2F-42CF-A76B-B3767ED40921Q28071388-186DC018-3AD9-4C4F-A6DC-C2B72EB6132AQ28079559-03417AD0-0F76-42F6-917E-D076F61E70AEQ28200932-2C36F9E1-B1AD-4596-8806-BCBAE93A84F7Q28268061-773EF673-FF03-4391-BEFD-04647443B6CCQ28268516-52DD7F88-E665-4021-AC02-9C8808C78DA0
P2860
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@ast
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@en
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@nl
type
label
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@ast
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@en
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@nl
altLabel
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
@en
prefLabel
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@ast
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@en
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@nl
P2093
P2860
P3181
P356
P1476
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
@en
P2093
C L Sawyers
I K Mellinghoff
J J Gibbons
M S Neshat
R Petersen
P2860
P304
P3181
P356
10.1073/PNAS.171076798
P407
P577
2001-08-28T00:00:00Z